Bolt Biotherapeutics Inc. (BOLT)
Bolt Biotherapeutics Statistics
Share Statistics
Bolt Biotherapeutics has 38.27M shares outstanding. The number of shares has increased by 0.38% in one year.
| Shares Outstanding | 38.27M |
| Shares Change (YoY) | 0.38% |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | 49.1% |
| Shares Floating | 25.2M |
| Failed to Deliver (FTD) Shares | 6.23K |
| FTD / Avg. Volume | 3.99% |
Short Selling Information
The latest short interest is 65.99K, so 0.17% of the outstanding shares have been sold short.
| Short Interest | 65.99K |
| Short % of Shares Out | 0.17% |
| Short % of Float | 0.26% |
| Short Ratio (days to cover) | 0.54 |
Valuation Ratios
The PE ratio is -0.61 and the forward PE ratio is -0.56. Bolt Biotherapeutics's PEG ratio is 0.03.
| PE Ratio | -0.61 |
| Forward PE | -0.56 |
| PS Ratio | 5.38 |
| Forward PS | 0.7 |
| PB Ratio | 0.38 |
| P/FCF Ratio | -0.61 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Bolt Biotherapeutics Inc. has an Enterprise Value (EV) of 51.76M.
| EV / Earnings | -0.75 |
| EV / Sales | 6.57 |
| EV / EBITDA | -0.7 |
| EV / EBIT | -0.68 |
| EV / FCF | -0.74 |
Financial Position
The company has a current ratio of 5.17, with a Debt / Equity ratio of 0.18.
| Current Ratio | 5.17 |
| Quick Ratio | 5.17 |
| Debt / Equity | 0.18 |
| Total Debt / Capitalization | 15.21 |
| Cash Flow / Debt | -3.44 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.61% and return on capital (ROIC) is -57.31%.
| Return on Equity (ROE) | -0.61% |
| Return on Assets (ROA) | -0.43% |
| Return on Capital (ROIC) | -57.31% |
| Revenue Per Employee | 78.76K |
| Profits Per Employee | -691.97K |
| Employee Count | 100 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -60.33% in the last 52 weeks. The beta is 0.95, so Bolt Biotherapeutics's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -60.33% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.64 |
| Relative Strength Index (RSI) | 43.81 |
| Average Volume (20 Days) | 155.9K |
Income Statement
In the last 12 months, Bolt Biotherapeutics had revenue of 7.88M and earned -69.2M in profits. Earnings per share was -1.83.
| Revenue | 7.88M |
| Gross Profit | 5.99M |
| Operating Income | -76.2M |
| Net Income | -69.2M |
| EBITDA | -74.34M |
| EBIT | -76.2M |
| Earnings Per Share (EPS) | -1.83 |
Balance Sheet
The company has 10.81M in cash and 20.22M in debt, giving a net cash position of -9.41M.
| Cash & Cash Equivalents | 10.81M |
| Total Debt | 20.22M |
| Net Cash | -9.41M |
| Retained Earnings | -364.29M |
| Total Assets | 109.33M |
| Working Capital | 39.06M |
Cash Flow
In the last 12 months, operating cash flow was -69.53M and capital expenditures -206K, giving a free cash flow of -69.73M.
| Operating Cash Flow | -69.53M |
| Capital Expenditures | -206K |
| Free Cash Flow | -69.73M |
| FCF Per Share | -1.84 |
Margins
Gross margin is 76.08%, with operating and profit margins of -967.45% and -878.58%.
| Gross Margin | 76.08% |
| Operating Margin | -967.45% |
| Pretax Margin | -878.58% |
| Profit Margin | -878.58% |
| EBITDA Margin | -943.91% |
| EBIT Margin | -967.45% |
| FCF Margin | -885.36% |
Dividends & Yields
BOLT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -381.25% |
| FCF Yield | -381.08% |
Analyst Forecast
The average price target for BOLT is $1.25, which is 160.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.25 |
| Price Target Difference | 160.4% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -6.64 |
| Piotroski F-Score | 3 |